Myelodysplastic Syndromes

April 11th 2024

The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant vs those who did not.

April 4th 2024

This study builds on previous evidence for lenalidomide-induced selective advantage for TP53-mutant clones.

March 26th 2024

The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.

March 16th 2024

The report found the therapy boosted rates of transfusion independence, particularly among patients who had a low baseline transfusion rate.